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Age-related macular degeneration (AMD) is the leading cause of visual loss in older population. Angiogenesis is an important fac-
tor associated with the development of CNV due to AMD. Treatment of CNV with intravitreal anti-VEGF monotherapy is curren-
tly the standard of care. However, not all patients respond to monotherapy, and modiﬁed anti-VEGF treatment regimen and com-
binationtherapymaytargetreducingtreatmentfrequencyorimprovingvisualoutcome.Thispaperreviewsthemanyclinicaltrials
that have been performed utilizing several treatment regimens. While many trials have shown that this variable therapy is justiﬁ-
able, further study is required to determine correct regimens and dosage.
1.Introduction
Age-related macular degeneration (AMD) is one of the lead-
ing causes of substantial and irreversible vision loss. The
prevalence of AMD can be expected to increase along with
life expectancy, which has risen steadily [1, 2]. Without treat-
ment, the neovascular form of AMD leads to severe quality-
of-life loss within a short time period and considerable eco-
nomic burden.
VEGF is a key mediator involved in the control of angio-
genesis and vascular permeability and has been shown to be
induced by hypoxia in cultured human RPE [3]. Vascular
endothelial growth factor A (VEGF-A) is the most potent
promoter of angiogenesis and vascular permeability within
theVEGFfamilyanditsroleinthepathogenesisofneovascu-
larAMDiswellrecognized[4,5].Theadventofintravitreous
VEGF inhibitors has revolutionized the management of neo-
vascular AMD. Yet, frequently, indeﬁnite injections of VEGF
blocking agents introduce a signiﬁcant treatment burden for
patients with neovascular AMD. Many studies on modiﬁed
treatment regimens have been performed in an attempt to
mitigate this burden without compromise to visual acuity
outcomes. Meanwhile, various randomized clinical trials on
combination therapies and eﬀorts to develop new pharma-
cologic agents are ongoing.
2.MaterialandMethods
A MEDLINE search of the English language literature from
1990 to present was conducted. The search strategy was
based on combinations of medical subject headings (MeSH)
and keywords and was not restricted to speciﬁc journals
or years of publication. The searches were supplemented by
handsearching the bibliographies of included studies and re-
views.
3. Results
3.1. Three Antivascular Endothelial Growth Factor (VEGF)
Therapies. Three antivascular endothelial growth factor
(VEGF) therapies are currently used for the treatment of pa-
tients with wet age-related macular degeneration (AMD):
pegaptanib (Macugen, Pﬁzer, UK), ranibizumab (Lucentis,
Novartis, UK), and bevacizumab (Avastin, Roche, UK).
Petaganib is an oligonucleotide aptamer and was the ﬁrst
VEGF antagonist to be approved by the US Food and Drug2 Journal of Ophthalmology
Administration for use in wet AMD. However, wet AMD
patients treated with petaganib still experience visual decline
[2, 6]. For this reason, petaganib was seldom used now.
Ranibizumab (Lucentis) is also a humanized antibody
fragment against VEGF which was speciﬁcally designed for
intraocular use as a smaller antibody fragment to penetrate
through the retina better. The Food and Drug Administra-
tion(FDA)approvedranibizumabfortreatmentofsubfoveal
neovascular AMD in June, 2006. It was the ﬁrst treatment for
AMD shown to improve visual acuity in a substantial per-
centage of patients.
Bevacizumab (Avastin) is a recombinant humanized mo-
noclonal immunoglobulin antibody that inhibits the activity
of VEGF. It has a similar action and is related to the rani-
bizumab compound with respect to its structure. Bevacizu-
mabwasapprovedbytheFDAforthetreatmentofmetastatic
colorectal cancer in 2004, but it has not been licensed for
the treatment of wet AMD or any other ocular conditions.
However, it is recently used oﬀ-label worldwide not only for
wet AMD but also for other ocular disease entities associated
with macular edema and abnormal vessel growth.
Since 2009, there have been increasing number of studies
that have compared the properties of ranibizumab and beva-
cizumab and investigated their eﬃcacy on AMD. The pivotal
phase III Minimally Classic/Occult Trial of the Anti-VEGF
Antibody Ranibizumab in the Treatment of Neovascular
AMD (MARINA) [7] and the Anti-VEGF Antibody for
the Treatment of Predominantly Classic CNV in AMD
(ANCHOR) trial [8, 9] demonstrated best-corrected visual
acuity (BCVA) outcomes far superior to any previously
published study in the treatment of this disease. At the
end of 24 months in the MARINA trial, signiﬁcantly more
ranibizumab-treatedpatientshadmaintained(lost<15Early
Treatment Diabetic Retinopathy Study (ETDRS) letters) or
improved vision than sham-injected patients. Indeed, 90–
95% of patients treated with 0.3 and 0.5mg ranibizumab
maintained vision compared with 53–64% of control pa-
tients. Over the same period, vision improved in 25–34% of
treated eyes, compared with 4-5% of sham-injected patients.
In the ANCHOR trial, ranibizumab was compared with
verteporﬁn photodynamic therapy (PDT) and demonstrated
similar ﬁndings: 90–96% of the ranibizumab-treated versus
64–66% of the PDT-treated patients maintained vision,
whereas 34–41% versus 6% of each group, respectively,
gained more than 15 letters. These outcomes were signiﬁ-
cantly better (P<0.001) than those achieved by the control
groups.
Patient-reported outcomes were also assessed in the
ANCHOR and MARINA trials to measure the inﬂuence of
the ranibizumab-mediated improvement in VA on quality of
life. The data demonstrated that patients treated with rani-
bizumab were more likely to report improvements in near
activities, distance activities, and vision-speciﬁc dependency
which were maintained over the 2-year duration of the trial
[10, 11]. These data demonstrate that the clinical impro-
vements seen with ranibizumab treatment translate into
meaningful beneﬁts for the patient.
Bevacizumab, the predecessor of ranibizumab, is a full-
length monoclonal antibody that binds to and blocks the
action of all VEGF isoforms. Numerous retrospective [12–
15] and prospective studies [16–18] of intravitreal bevaci-
zumab have reported its eﬃcacy for neovascular AMD and
low rates of treatment-related complications [19]. Although
a number of these studies were uncontrolled, relatively small
in sample size, of limited followup, and varied with regard
to outcome measures and retreatment criteria, the reported
eﬃcacy of bevacizumab coupled with its low cost when utili-
zed as an intraocular agent has propelled its adoption world-
wide.
In clinical practice, many retinal physicians have extrap-
olated the data and continued using bevacizumab. A formal
head-to-head comparison of bevacizumab and ranibizumab
is being conducted by the National Eye Institute of the
National Institute of Health in the Comparisons of Age-Re-
lated Macular Degeneration Treatment Trials (CATTs) [20,
21]. The CATT study design includes four treatment arms:
either bevacizumab or ranibizumab on a variable schedule
and either bevacizumab or ranibizumab on a ﬁxed monthly
schedule for 1 year followed by random assignment to either
continued monthly injections or a variable schedule based
on the treatment response. The primary outcome measure is
meanchangeinBCVA;secondaryoutcomemeasuresinclude
number of treatments, anatomical changes in the retina, ad-
verse events, and cost. Preliminary results are reported in
2011 and will provide insight into how ranibizumab and be-
vacizumab compare with each other within the context of
either a ﬁxed monthly or traditional pro re nata (PRN) ap-
proach. At 1 year, bevacizumab and ranibizumab had equiv-
alent eﬀects on visual acuity when administered according
to the same schedule. Bevacizumab administered monthly
was equivalent to ranibizumab administered monthly, with
8.0 and 8.5 letters gained, respectively. Bevacizumab admin-
istered as needed was equivalent to ranibizumab as needed,
with 5.9 and 6.8 letters gained, respectively. Ranibizumab
given as needed with monthly evaluation had eﬀects on
vision that were equivalent to those of ranibizumab admin-
istered monthly, although the comparison between beva-
cizumab as needed and monthly bevacizumab was inclusive.
Diﬀerences in rated of serious adverse events require further
study.
3.2. Modiﬁed Treatment Regimens. The prospect of indef-
initely adhering to the monthly treatment schedules of
MARINA and ANCHOR has raised ocular and systemic
safety concerns as well as convenience and cost issues for
patient and physician alike. The identiﬁcation of alternative
dosing strategies capable of reducing the number of required
anti-VEGF injections while still achieving visual acuity out-
comes similar to those reached in the pivotal trials has since
been a subject of great interest.
The observed biphasic treatment eﬀect raised the possi-
bility that, after the initial 3-month loading phase, mainte-
nance of VA gain may be achieved with less frequent treat-
ments. A PIER trial evaluated ranibizumab administered
monthly for 3 months, followed by quarterly injections, and
compared this with sham treatment. Under this schedule,
ranibizumab did provide a signiﬁcant VA beneﬁt; a signiﬁ-
cantly greater number of patients achieved VA stabilizationJournal of Ophthalmology 3
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Figure 1: Fundus photograph of patients with hemorrhagic PED secondary to AMD. Fluorescein angiogram shows large hypoﬂuorescence
due to hemorrhage at macular lesion. Optical coherence tomography with large PED and subretinal ﬂuid. (a, c, e) Same section after 3 rani-
bizumab intravitreal injections. Complete resolution of the hemorrhagic PED with edema is illustrated. There was also improvement in
visual acuity (b, d, f).
at 24 months compared with patients receiving sham treat-
ment. However, subgroup analysis revealed that VA gains
observed during the ﬁrst 3 months of treatment were only
maintained in 40% of patients over the duration of the trial,
and for the remaining 60% quarterly dosing was not suitable
[22, 23]. Results for both ranibizumab doses in the PIER
trial (0.3 and 0.5mg) showed an initial mean improvement
in BCVA during the initiation phase with monthly dosing,
but after month 3 in the maintenance phase with quarterly
dosing, there was a gradual decline in mean BCVA to below
the pretreatment baseline ( 2.2 letters) at 12 months, which
remained unchanged at 24 months [23]( Figure 1).
More recently, the Eﬃcacy and Safety of Ranibizumab in
Patients with Subfoveal Choroidal Neovascularization Sec-
ondary to Age-Related Macular Degeneration (EXCITE)
study directly compared the PIER regimen with a ﬁxed
monthly treatment arm (0.3mg ranibizumab) [24]. Al-
though BCVA outcomes in the two quarterly treatment arms
fared better than those in the PIER study at 12 months (2.2
and 3.1 letters with 0.3 and 0.5mg ranibizumab, resp.), nei-
ther was as good as monthly dosing (0.9 letters). These sub-
optimal results demonstrate that, on average, quarterly treat-
mentisinferiortomonthlytreatment;thus,ithasneverbeen
adopted in practice. Subsequent to the PIER trial, further
investigation of a ﬂexible dosing approach was carried out.
The EXCITE trial directly compared a maintenance phase
of quarterly injections against the monthly regimen. Consis-
tent with previous observations, an initial gain was made in
the ﬁrst 3 months, after which patients receiving monthly
injections contributed to gain VA, whilst those receiving
quarterly injections showed a decrease from their 3-month
VA levels.
The current norm in clinical practice with ranibizumab
or bevacizumab is to implement an initiation/induction
phase followed by an individualized maintenance phase that
is modeled after one of two basic approaches: traditional
PRN [25] or “treat and extend” [26, 27]. Traditional PRN in-
volves both regular followup and treatment until the macula
is more or less free of exudation, with treatment thereafter
during the maintenance phase only in the presence of recur-
rent exudation. The original prospective studies that eva-
luated a PRN approach to the maintenance phase were
the Prospective Optical Coherence Tomography Imaging
of Patients with Neovascular AMD Treated with Intra-
Ocular Lucentis (PrONTO) study [28] and the Secondary to
Age-Related Macular Degeneration (SAILOR) study [29].4 Journal of Ophthalmology
More recently, the Study of Ranibizumab in Patients with
Subfoveal Choroidal Neovascularization Secondary to Age-
Related Macular Degeneration (SUSTAIN) study has con-
tributed additional data [30]. In each of these trials, patients
received three consecutive, monthly intravitreal injections
of ranibizumab for induction, followed by monthly oﬃce
visits. Thereafter, a PRN maintenance phase adhered to the
following retreatment criteria: loss of at least ﬁve ETDRS
letters, increase in central macular thickness on OCT of at
least 100µm, or new hemorrhage.
Of the three studies, the PrONTO study demonstrated
the best visual acuity results. The PrONTO study evaluated
an OCT guided, variable-dosing regimen with ranibizumab
(0.5mg) and showed that mean visual acuity improved by
9.3 ETDRS letters at 12 months. Over a 2-year period, mean
BCVA outcomes were similar to MARINA and ANCHOR
with a mean of 9.9 injections (5.6 in the ﬁrst year and 4.3 in
the second). In comparison, results from the SAILOR study
were not as good. In this study, the mean change in BCVA at
12 months from baseline was 0.5 and 1.7 letters in the treat-
ment-naiveandpreviouslytreatedgroups,respectively,atthe
0.3mg dose and 2.3 letters in both groups at 0.5mg. It is
worth noting that participants were not monitored as closely
in SAILOR as compared with PrONTO, averaging nine visits
through 1 year and a mean of 4.9 injections.
The 12-month results from SUSTAIN were slightly better
than those from SAILOR (mean BCVA from baseline of 3.6
letters), yet still not as good as the monthly treatment trials.
In contrast to SAILOR, participants in the SUSTAIN trial
were followed monthly (more like PrONTO) and the mean
number of injections over the ﬁrst year was higher at 5.6.
Other relatively large studies using a traditional PRN
approach have recently been published [31–33]. An analysis
ofthesereportshighlightsanimportanttrend:thebestvisual
acuity results come from the study with the greatest mean
number of treatments and closest followup, whereas the
poorest outcomes were observed in the study with the lowest
mean number of treatments and oﬃce visits. Unlike tradi-
tional PRN, a treat and extend approach initially involves
regular and frequent treatment until the macula is dry,
followed by a gradual extension of the treatment interval and
corresponding followup visit. Treatment interval extension
continues until there are signs of recurrence, at which point
the treatment interval is then reduced.
Kang and Roh [34, 35] recently published a retrospective
analysis that monthly injections were not given in contrast to
the three injections during the initial treatment period in the
PIER and PrONTO trials. This study minimized the num-
ber of injections given during 12 months of follow-up (a
mean of 4.07 injections were given over the 12 months). The
decreased need for retreatment is of great beneﬁt to both
patients and clinicians. These results may raise doubts about
the need for the three initial loading injections. They repor-
ted another study [35]; the mean number of injections given
in the 12 months period was 4.2 (range, 1–6). Patients were
also oﬀered reinjection with ranibizumab on an “as needed”
basis. Data showed that the percentage of patients (71.9%)
withnovisuallossorimprovedvisualacuitywascomparable
to the percentages in the monthly injection-based studies.
In addition, Gupta et al. evaluated a treat and extend ap-
proach with bevacizumab and found nearly identical results
at 12 months following a mean of 7.3 injections in the ﬁrst
year [33]. Although various methods for individualizing
maintenance therapy have been proposed, the optimal non-
monthly dosing regimen does not remain clear.
3.3. Combination Therapy: Photodynamic Therapy and Anti-
VEGF Therapy. The development and propagation of CNV
membranes involve proangiogenic factors, vascular permea-
bility molecules, and inﬂammatory proteins. Current stan-
dard treatment with monthly intravitreal injections of anti-
VEGF monotherapy can be limited to the angiogenic com-
ponent of CNV development and burdensome for both the
physicianandpatient. Patients aresubjectedto increasedrisk
with monthly treatments that may be lessened with treat-
ment options given with less frequency [36]. Combination
therapy with PDT proven to be eﬀective may not only have
a role in the treatment of CNV development but also may
provide synergy through blocking adverse eﬀects.
Photodynamic therapy was approved in 2000 by the FDA
for the treatment of CNV secondary to AMD. Treatment
involves intravenous administration of a light-sensitive dye
called verteporﬁn followed by laser-guided, location-speciﬁc
activation within the CNV membrane. Activation of the ver-
teporﬁn molecules incites a phototoxic event within blood
vessels, induces endothelial cell damage, platelet aggregation,
and eventually leads to thrombosis of vascular channels.
Treatment size is limited by the greatest linear diameter of
the CNV lesion being treated [37, 38].
While PDT is intended to speciﬁcally target CNV vessels,
collateral damage to surrounding blood vessels may lead to
ischemia of healthy tissue. Following PDT of a CNV mem-
brane, induced ischemia can lead to production of proangio-
genic factors, especially VEGF. Therefore, combining verte-
porﬁn PDT and anti-VEGF therapy may be beneﬁcial com-
pared with either modality alone, yielding longer treatment-
free intervals and requiring fewer intravitreal injections [37].
The RhuFab V2 Ocular Treatment Combining the Use of
Visudyne to Evaluate Safety (FOCUS) study is a multicen-
ter, randomized, single-blind study designed to evaluate the
safetyandeﬃcacyofstandardﬂuencePhotodynamictherapy
(sfPDT) in combination with intravitreal ranibizumab [39,
40]. It compared sfPDT to combination sfPDT and intravit-
real ranibizumab in the treatment of predominantly classic
CNV secondary to AMD. One-year data showed greater
visual stability in the patients treated with combination ther-
apy and 23.8% of patients experienced improvement in
visualacuity,comparedwith5%ofpatientstreatedwithPDT
monotherapyalone.ThenumberofretreatmentswithsfPDT
was decreased as well with 91% of patients treated with
sfPDT monotherapy requiring repeat treatment while only
28% of patients treated with combination therapy requiring
retreatment. Two-year data showed similar results with 88%
of combination-treated patients losing less than 15 lines of
vision versus 75% of sfPDT-alone treated patients. Combi-
nation therapy required an average of 0.4 repeat PDT treat-
ments compared with an average of 3.0 in the sfPDT group.Journal of Ophthalmology 5
3.4. Vascular Endothelial Growth Factor Trap-Eye. The most
eﬀective dosing regimen and monitoring program for anti-
VEGF therapy has yet to be ﬁrmly established but new treat-
ments are aimed at extending and improving on the eﬃcacy
of ranibizumab. VEGF Trap-Eye is a promising new anti-
VEGF drug (aﬂibercept ophthalmic solution; Regeneron
Pharmaceuticals Inc., Tarrytown, NY, USA). Structurally,
VEGF Trap-Eye is a fusion protein of key binding domains
of human VEGFR-1 and -2 combined with a human IgG
Fc fragment. Functionally, VEGF Trap-Eye acts as a receptor
decoy with high aﬃnity for all VEGF isoforms, binding more
tightly. VEGF Trap-Eye diﬀers from established anti-VEGF
therapies in its higher binding aﬃnity for VEGF-A and its
blockage of placental growth factors-1 and -2 [41, 42].
Recently, the 1-year results of two parallel randomized,
double-masked phase 3 clinical trials (VIEW 1 and VIEW 2)
ontheeﬃcacyandsafetyofVEGFTrap-Eyeforthetreatment
of neovascular AMD were reported [42]. Phase I data de-
monstrated acceptable safety and tolerability of VEGF Trap-
Eye in the treatment of neovascular AMD, and in Phase II
study data, patients dosed in a similar fashion to the
PrONTO trial demonstrated stabilization of their vision
that was similar to previous studies of ranibizumab at 1
year. All dosing regimens of VEGF Trap-Eye, including 2mg
bimonthly,mettheprimaryendpointofnoninferioritycom-
pared with monthly 0.5mg ranibizumab with regard to the
percentage of patients with maintenance (loss of <15 ETDRS
letters) or improvement in vision. A greater mean improve-
ment in visual acuity compared with monthly 0.5mg ranibi-
zumab at 1 year versus baseline represented the secondary
endpoint of the study. In both the North American study
(VIEW1)andinternationalstudy(VIEW2),morethan95%
of patients in each of the following VEGF Trap-Eye dosing
groups achieved maintenance of vision compared with 94%
of patients on monthly ranibizumab: 0.5mg monthly, 2mg
monthly, and 2mg every 2 months. In VIEW 1, patients on
2mg monthly dosing achieved the secondary endpoint with
a mean gain of 10.9 ETDRS letters compared with 8.1 for
monthly ranibizumab (P<0.01) [42].
In contrast to current anti-VEGF antibodies, which are
rapidly cleared, the VEGF Trap-Eye is relatively degraded
moreslowly.Duetoitshighbindingaﬃnityandtheabilityto
safelyinjecthighdosesintotheeye,VEGFTrap-Eyemayhave
longer duration of eﬀect in the eye. Its adoption into clini-
calpracticewilldependoneﬃcacyat4-and8-weekintervals.
If eﬀective at 4- and 8-week intervals, VEGF Trap-Eye oﬀers
a competitive price advantage over ranibizumab and the op-
portunity to signiﬁcantly reduce treatment burden on pa-
tients and physicians.
3.5. Future Therapies for Age-Related Macular Degeneration.
AMD is a complex mechanism in which a variety of medi-
ators are likely to be involved. Any of these could serve as a
potential target for the treatment of ocular neovasculariza-
tion. In preclinical and clinical studies, several targets have
already been evaluated. For example, treatment regimes of
a drug blocking the transduction of the signaling cascade
within the cell (tyrosine kinase) and one inhibiting the fur-
ther intracellular production of VEGF (small interfering
RNA) might achieve a better visual outcome [43]. Yet the
eﬃcacy, safety, treatment interval, and cost of these treat-
ments remain undetermined. But the increasing number of
drugs aﬀecting neovascular growth and leakage by diﬀerent
mechanisms will potentially allow various combination stra-
tegies.
4. Conclusion
Age-related macular degeneration (AMD) aﬀects the many
elderly population. Before the development of anti-VEGF,
the diagnosis of neovascular AMD meant frequently loss of
useful vision. But targeted anti-VEGF therapy has signiﬁ-
cantly improved the treatment of neovascular AMD.
Theappropriatemethod,dose,andtypesofcombination
therapy remain undetermined but randomized trials are cur-
rentlycontinuingandwillprovidecriticalinsightintothecli-
nical applicability of new regimens. It hopefully can help in
the treatment of resistant CNV with longer duration and less
frequency between treatments.
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